rolipram has been researched along with Cirrhosis in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Rolipram has a good anti-fibrosis effect after inhibiting the activity of PDE4." | 4.02 | Rolipram plays an anti-fibrotic effect in ligamentum flavum fibroblasts by inhibiting the activation of ERK1/2. ( Chen, Y; Fan, J; Guo, Q; Meng, D; Song, G; Wu, L; Xu, G; Xu, L; Xu, P, 2021) |
| "Specific inhibition of PDE4 by rolipram and apremilast had potent antifibrotic effects in bleomycin-induced skin fibrosis models, in the topoisomerase I mouse model and in murine sclerodermatous chronic graft-versus-host disease." | 3.85 | Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. ( Bergmann, C; Beyer, C; Distler, JHW; Kittan, N; Maier, C; Ramming, A; Schett, G; Weinkam, R, 2017) |
| " We compared the effect of rolipram, a selective PDE4 inhibitor, with steroids on the clinical course of experimental colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS)." | 3.73 | Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. ( Guarner, F; Malagelada, JR; Medina, C; Mourelle, M; Salas, A; Videla, S; Vilaseca, J, 2006) |
| "Rolipram was effective in inhibiting angiogenesis as assessed by hemoglobin content and VEGF levels in subcutaneous implants (about 40% with both doses) but failed to exert this activity in intraperitoneal implants." | 1.35 | Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. ( Andrade, SP; Araújo, FA; Ferreira, MA; Mendes, JB; Moura, SA; Rocha, MA, 2009) |
| "Renal interstitial inflammation is a consequence of unilateral ureteral obstruction (UUO)." | 1.33 | A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy. ( Chevalier, RL; Forbes, MS; Lange-Sperandio, B; Linden, J; Okusa, MD; Thornhill, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, L | 1 |
| Xu, L | 1 |
| Chen, Y | 1 |
| Xu, G | 1 |
| Guo, Q | 1 |
| Meng, D | 1 |
| Fan, J | 1 |
| Song, G | 1 |
| Xu, P | 1 |
| Costa, WC | 1 |
| Beltrami, VA | 1 |
| Campolina-Silva, GH | 1 |
| Queiroz-Junior, CM | 1 |
| Florentino, RM | 1 |
| Machado, JR | 1 |
| Martins, DG | 1 |
| Gonçalves, WA | 1 |
| Barroso, LC | 1 |
| Freitas, KM | 1 |
| de Souza-Neto, FP | 1 |
| Félix, FB | 1 |
| da Silva, RF | 1 |
| Oliveira, CA | 1 |
| Câmara, NOS | 1 |
| Rachid, MA | 1 |
| Teixeira, MM | 1 |
| Rezende, BM | 1 |
| Pinho, V | 1 |
| Elnagdy, M | 1 |
| Wang, Y | 1 |
| Rodriguez, W | 1 |
| Zhang, J | 1 |
| Bauer, P | 1 |
| Wilkey, DW | 1 |
| Merchant, M | 1 |
| Pan, J | 1 |
| Farooqui, Z | 1 |
| Cannon, R | 1 |
| Rai, S | 1 |
| Maldonado, C | 1 |
| Barve, S | 1 |
| McClain, CJ | 1 |
| Gobejishvili, L | 1 |
| Maier, C | 1 |
| Ramming, A | 1 |
| Bergmann, C | 1 |
| Weinkam, R | 1 |
| Kittan, N | 1 |
| Schett, G | 1 |
| Distler, JHW | 1 |
| Beyer, C | 1 |
| Mendes, JB | 1 |
| Rocha, MA | 1 |
| Araújo, FA | 1 |
| Moura, SA | 1 |
| Ferreira, MA | 1 |
| Andrade, SP | 1 |
| Lange-Sperandio, B | 1 |
| Forbes, MS | 1 |
| Thornhill, B | 1 |
| Okusa, MD | 1 |
| Linden, J | 1 |
| Chevalier, RL | 1 |
| Videla, S | 1 |
| Vilaseca, J | 1 |
| Medina, C | 1 |
| Mourelle, M | 1 |
| Guarner, F | 1 |
| Salas, A | 1 |
| Malagelada, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis[NCT03529955] | Phase 2 | 8 participants (Actual) | Interventional | 2018-06-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"MMT-8 (Manual Muscle Testing-8) score is a validated tool to assess muscle strength. Calculate the mean change in MMT-8 score at 3 and 6 month(s) compared to baseline in patients with muscle disease.~Units: Units on a scale. Scale goes from 0-150. 150 is perfect strength." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
| Intervention | score on a scale (Mean) |
|---|---|
| MMT-8 Score at 3 Months | 143.3 |
| MMT-8 Score at 6 Months | 144.5 |
"Dermatology Life Quality Index (DLQI) is a validated tool to measure quality of life in patients with skin disease. Complete response is defined by a DLQI of zero at 3, and 6 months. Partial response is defined by a decrease of DLQI of at least 5 points at 3, and 6 months compared to baseline. Calculation is performed as the DLQI at 3, and 6 months minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~Units : Units on a scale from 0-30, higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
| Intervention | score on a scale (Mean) |
|---|---|
| DLQI Score at 3 Months | 6.3 |
| DLQI Score at 6 Months | 4.2 |
"The durability of response will be measured using the CDASI activity score at 6 months minus CDASI activity score at 3 months. Complete response durability is defined as zero or minus difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Partial response durability is defined as >4 points difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 6 months compared to data collected at 3 months
| Intervention | score on a scale (Mean) |
|---|---|
| CDASI Score at 3 Months | 16.9 |
| CDASI Score at 6 Months | 14 |
"Cutaneous dermatomyositis disease area and severity index (CDASI) activity score is a validated tool to measure skin disease activity in dermatomyositis. The overall response rate (ORR) includes partial and complete responses. Complete response is defined by a CDASI activity score of zero. Partial response is defined by a decrease of CDASI activity score of at least 4 points. Calculation is performed as the CDASI activity score at 3 month(s) minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Dermatomyositis Patients With Refractory Cutaneous Disease | 7 |
"The proportion of participants experiencing adverse events and serious adverse events was measured over 7 months period (6 months during the study and 1 month follow up) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.~Grade refers to severity of the AE. The CTCAE displays Grades 1 to 5 with unique clinical descriptions of severity for each AE:~Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental Activity of Daily Living (ADL) Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated Grade 5 Death related to AE All adverse events subjects experienced were grade 1 or 2 which is mild to moderate in severity." (NCT03529955)
Timeframe: 7 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Headache Grade 1-2 | Nausea Grade 1-2 | Diarrhea Grade 1-2 | Herpes Zoster Grade 1-2 | Influenza Grade 1-2 | Pneumonia Grade 1-2 | Acute sinusitis Grade 1-2 | Hypertension Grade 1-2 | Ocular pressure Grade 1-2 | |
| Dermatomyositis Patients With Refractory Cutaneous Disease | 7 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 1 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in gene expression profiling and immunohistochemistry stain. Gene expression profiling will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
| Intervention | Change (Number) | |
|---|---|---|
| Down regulated genes | Up regulated genes | |
| Skin Biopsy at 3 Months Into Apremilast Therapy for Gene Expression Profiling | 123 | 72 |
| Skin Biopsy at Baseline for Gene Expression Profiling | 0 | 0 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in immunohistochemistry stain. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
| Intervention | Percentage of positive cell detection (Mean) | |
|---|---|---|
| STAT1 | STAT3 | |
| Skin Biopsy at 3 Months Into Apremilast Therapy for IHC | 50.1 | 17.4 |
| Skin Biopsy at Baseline for IHC | 96.2 | 44.3 |
7 other studies available for rolipram and Cirrhosis
| Article | Year |
|---|---|
Rolipram plays an anti-fibrotic effect in ligamentum flavum fibroblasts by inhibiting the activation of ERK1/2.
Topics: Fibroblasts; Fibrosis; Humans; Ligamentum Flavum; MAP Kinase Signaling System; Rolipram; Transformin | 2021 |
Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Fibrosis; Hypercholes | 2023 |
Increased expression of phosphodiesterase 4 in activated hepatic stellate cells promotes cytoskeleton remodeling and cell migration.
Topics: Actins; Animals; Cell Movement; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytoskeleton; Fibrosis | 2023 |
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Topics: Animals; Bleomycin; Cell Differentiation; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 4; Cy | 2017 |
Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice.
Topics: Administration, Oral; Animals; Chemokine CCL2; Collagen; Disease Models, Animal; Fibrosis; Inflammat | 2009 |
A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Apoptosis; Cell Proliferation; Cyclic Nucleotide Phosp | 2005 |
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Chronic Disease; Colitis; Colon; Cyclic Nucleotide Pho | 2006 |